Regenerative Medical Technology Group Inc. Annual Report: A Year in Review

I’m here to help you understand how Regenerative Medical Technology Group Inc. (RMTG) performed this year. Instead of reading through dense financial filings, use this guide to see the "big picture" and decide if this company fits your investment goals.

1. What does this company do?

RMTG is a one-stop shop for regenerative medicine, including stem cell therapies, exosomes, and anti-aging treatments. They run a closed-loop system: they train doctors through the International Society for Stem Cell Application (ISSCA), manufacture their own medical products via their subsidiary Cellgenic, and operate their own clinics. In 2025, they focused on global growth, using their Cancún summit to train over 470 medical professionals and launch new standardized treatment protocols.

2. Financial performance: Did they make money?

To be direct: No. The company is currently losing money. Their auditors issued a "going concern" warning, which signals serious doubt regarding the company’s ability to remain in business. RMTG is struggling with ongoing losses and currently lacks the cash reserves necessary to fund daily operations or satisfy its debt obligations.

3. Major wins and challenges

Wins: They are building a "flywheel" effect. By training doctors through ISSCA, they create a loyal customer base that purchases their Cellgenic products and adopts their specific treatment protocols. They have also successfully expanded their footprint into Brazil, Pakistan, and the Dominican Republic.

Challenges: The company is in a precarious financial position. They have over $1.1 million in loans that have already matured and are currently in default. While lenders have not yet forced immediate repayment, this creates a significant risk. If lenders demand payment, it could trigger a much larger $16.6 million debt obligation that the company is currently unable to cover.

4. Financial health: Are they on solid ground?

No. Their financial health is very shaky. Because they operate entirely outside the U.S., they are vulnerable to currency fluctuations; if local currencies in their operating regions drop against the dollar, the company’s reported profit suffers. They are also burning through cash to fund projects like their delayed Dubai facility while managing significant legacy debt.

5. Key risks: What could hurt the stock price?

This is a high-risk investment. Beyond the "going concern" warning, investors should consider:

• Debt Default: If lenders demand payment on the $1.1 million in defaulted loans, the company could face bankruptcy or be forced to issue more shares, which would dilute your ownership.
• Geopolitical Risk: Because they operate entirely abroad, they are subject to foreign laws and political instability, which can disrupt business operations unexpectedly.
• Market Adoption: Stem cell therapy is still an emerging field, and skepticism in the medical community makes it expensive and slow to win over new customers.

6. Competitive positioning

They are attempting to pivot toward a tech-focused model by launching AI tools to help doctors track patient outcomes. By adding these digital tools, they hope to transition from a traditional medical supplier to a software-style business, which could potentially create steady, recurring income.

7. Future outlook

Management is doubling down on their strategy to keep doctors locked into their ecosystem. However, the company’s survival depends on securing new capital or successfully restructuring their $16.6 million debt to avoid a financial crisis.

Final Thought for Investors: RMTG is currently in a "turnaround or bust" phase. If you are considering an investment, weigh the potential of their global medical ecosystem against the very real risk of bankruptcy due to their current debt defaults and lack of cash flow. This is a speculative play that requires a high tolerance for risk.